Jlb & Associates Has Boosted Abbvie (ABBV) Stake; Akcea Therapeutics (AKCA) Sellers Increased By 7.76% Their Shorts

January 14, 2018 - By Ruchi Gupta

Jlb & Associates Inc increased Abbvie (ABBV) stake by 8.76% reported in 2017Q3 SEC filing. Jlb & Associates Inc acquired 5,285 shares as Abbvie (ABBV)’s stock rose 6.17%. The Jlb & Associates Inc holds 65,634 shares with $5.83M value, up from 60,349 last quarter. Abbvie now has $160.19 billion valuation. The stock increased 1.08% or $1.07 during the last trading session, reaching $100.34. About 4.37 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 14, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Akcea Therapeutics Incorporated (NASDAQ:AKCA) had an increase of 7.76% in short interest. AKCA’s SI was 3.53M shares in January as released by FINRA. Its up 7.76% from 3.27M shares previously. With 240,700 avg volume, 15 days are for Akcea Therapeutics Incorporated (NASDAQ:AKCA)’s short sellers to cover AKCA’s short positions. The stock decreased 1.22% or $0.21 during the last trading session, reaching $17. About 147,759 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. Stifel Nicolaus initiated it with “Buy” rating and $1900 target in Tuesday, August 8 report. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, November 7. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 31. The rating was initiated by BMO Capital Markets with “Buy” on Tuesday, August 8.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.13 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

Since July 31, 2017, it had 0 insider buys, and 8 insider sales for $45.57 million activity. Gosebruch Henry O had sold 300 shares worth $21,127 on Monday, July 31. Michael Robert A. sold 6,699 shares worth $589,512. Another trade for 193,131 shares valued at $13.71 million was made by GONZALEZ RICHARD A on Monday, August 7. On Monday, December 18 the insider RICHMOND TIMOTHY J. sold $8.57 million. $14.07M worth of stock was sold by Schumacher Laura J on Thursday, December 14. 8,300 shares valued at $705,655 were sold by SALEKI-GERHARDT AZITA on Monday, September 11.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc has $120.0 highest and $6 lowest target. $83.22’s average target is -17.06% below currents $100.34 stock price. Abbvie Inc had 70 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Monday, December 7. As per Friday, October 13, the company rating was maintained by UBS. The firm earned “Buy” rating on Friday, August 18 by Jefferies. The rating was downgraded by Citigroup to “Neutral” on Monday, November 28. The firm has “Buy” rating given on Friday, July 14 by Jefferies. The stock of AbbVie Inc. (NYSE:ABBV) has “Outperform” rating given on Friday, February 5 by William Blair. The stock has “Buy” rating by Jefferies on Thursday, May 25. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) rating on Wednesday, October 11. BMO Capital Markets has “Hold” rating and $66.0 target. On Thursday, September 28 the stock rating was upgraded by Deutsche Bank to “Hold”. The firm earned “Buy” rating on Tuesday, February 23 by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>